close
hp-tabs-0 https://www.fenwick.com/PublishingImages/Home%20Page%20Images/Fall%202019/home0.jpg, Fenwick Represents Arcutis | Biotherapeutics in $183.3M IPO Fenwick Represents Arcutis | Biotherapeutics in $183.3M IPO Fenwick represented Arcutis Biotherapeutics, a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet immuno-dermatology needs, in its initial public offering of approximately $183.3 million. 1 https://www.fenwick.com/experience/Pages/Fenwick-Represents-Arcutis-Biotherapeutics-Initial-Public-Offering.aspx hp-tabs-1 https://www.fenwick.com/PublishingImages/Home%20Page%20Images/Fall%202019/home2.jpg, Fenwick Insights Fenwick Insights INSIGHTS Fenwick’s latest survey compares the results of the 2019 proxy season in Silicon Valley with other large Bay Area public companies. 2 https://www.fenwick.com/Publications/Pages/2019-Proxy-Season-Results-in-Silicon-Valley-and-Large-Companies-Nationwide.aspx hp-tabs-2 https://www.fenwick.com/PublishingImages/Home%20Page%20Images/Fall%202019/home1.jpg, TOP TIER Law360 has named Fenwick a Capital Markets Group of the Year on the publication’s annual list that recognizes leadership in landmark matters and overall excellence. 3 https://www.fenwick.com/Media/Pages/Fenwick-Named-Law360-Capital-Markets-Group-of-the-Year.aspx hp-tabs-3 https://www.fenwick.com/PublishingImages/Home%20Page%20Images/Fall%202019/home4.jpg, Client Spotlight Client Spotlight CLIENT SPOTLIGHT Fenwick is guiding biotech company Audentes Therapeutics in its pending $3B acquisition by Astellas Pharma. 4 https://www.fenwick.com/experience/Pages/Fenwick-Represents-Audentes-Therapeutics-in-Pending-3-Billion-Acquisition-by-Astellas-Pharma.aspx hp-tabs-4 https://www.fenwick.com/PublishingImages/Home%20Page%20Images/Fall%202019/home3.jpg, FIRMWIDE Byron Dailey has joined Fenwick as a corporate partner in the firm’s Seattle office. He will lead Fenwick’s private investment funds practice. 5 https://www.fenwick.com/Media/Pages/Fenwick-Adds-to-Leading-Corporate-Practice-with-Partner-Byron-Dailey.aspx hp-tabs-0 https://www.fenwick.com/PublishingImages/Home%20Page%20Images/Fall%202019%20Mobile/Mobile-1.jpg, Fenwick Represents | Arcutis Biotherapeutics | in $183.3M IPO Fenwick Represents | Arcutis Biotherapeutics | in $183.3M IPO Fenwick represented Arcutis Biotherapeutics, a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet immuno-dermatology needs, in its initial public offering of approximately $183.3 million. https://www.fenwick.com/experience/Pages/Fenwick-Represents-Arcutis-Biotherapeutics-Initial-Public-Offering.aspx hp-tabs-1 https://www.fenwick.com/PublishingImages/Home%20Page%20Images/Fall%202019%20Mobile/Mobile-2.jpg, Fenwick Insights Fenwick Insights INSIGHTS Fenwick’s latest survey compares the results of the 2019 proxy season in Silicon Valley with other large Bay Area public companies. https://www.fenwick.com/Publications/Pages/2019-Proxy-Season-Results-in-Silicon-Valley-and-Large-Companies-Nationwide.aspx hp-tabs-2 https://www.fenwick.com/PublishingImages/Home%20Page%20Images/Fall%202019%20Mobile/Mobile-3.jpg, TOP TIER Law360 has named Fenwick a Capital Markets Group of the Year on the publication’s annual list that recognizes leadership in landmark matters and overall excellence. https://www.fenwick.com/Media/Pages/Fenwick-Named-Law360-Capital-Markets-Group-of-the-Year.aspx hp-tabs-3 https://www.fenwick.com/PublishingImages/Home%20Page%20Images/Fall%202019%20Mobile/Mobile-4.jpg, Client Spotlight CLIENT SPOTLIGHT Fenwick is guiding biotech company Audentes Therapeutics in its pending $3B acquisition by Astellas Pharma. https://www.fenwick.com/experience/Pages/Fenwick-Represents-Audentes-Therapeutics-in-Pending-3-Billion-Acquisition-by-Astellas-Pharma.aspx hp-tabs-4 https://www.fenwick.com/PublishingImages/Home%20Page%20Images/Fall%202019%20Mobile/Mobile-5.jpg, FIRMWIDE FIRMWIDE Byron Dailey has joined Fenwick as a corporate partner in the firm’s Seattle office. He will lead Fenwick’s private investment funds practice. https://www.fenwick.com/Media/Pages/Fenwick-Adds-to-Leading-Corporate-Practice-with-Partner-Byron-Dailey.aspx